Junshi Bio intends to introduce IL-2 series of products for US$88 million.

Under the agreement, Anwita will grant Regeneron a sole license to use the Anti-HSA-IL2N alpha products and related ANWITA technologies and intellectual property rights agreed upon in the License Agreement, or to use exclusive licenses in conjunction with Regeneron Bio proprietary products, including IL-2N alpha proteins, Anti-HSA-IL-2N alpha fusion proteins and derivatives, and to develop and commercialize licensed products within the licensed area.
addition, Regency Hastert has the right to sub-license the relevant authorizations and to have an exclusive right to conduct clinical trials outside the licensed area.
HSA-IL-2N alpha is an independently developed series of IL-2 products developed by Anwita, based on the company's AWT-P1790, which removes CD25 binding forces, further optimizes CD122 binding forces, and uses Anti-HSA nanoproteins to extend the half-life of the body, making them the next generation of highly efficient, low-toxic IL-2 products.
-2 (IL-2) is a globulin that plays an important role in maintaining the normal functioning of T lymphocytes and natural killer (NK) cells.
IL-2 is mainly produced by activated T-cells, which promote the proliferation and differentiation of T-cells, maintain T-cell activity, stimulate the production, proliferation and activation of NK cells, and induce the production of cytotoxic T lymphocytes (CTL) and induce and activate lymphocyte-activated killer cells (LAK) and tumor-immersed lymphocytes.
IL-2 has good antiviral, anti-cancer and wide clinical potential.
As of the end of August this year, Regency Bio had reached a partnership with Zhidao Bio to obtain exclusive licenses from the latter to develop, commercialize and use proprietary technologies for the worldwide development, commercialization and use of IL-2 drugs (LTC002).
the deal involved a total of 959 million yuan.
it's worth noting that this isn't the first time Regency has worked with Anwita.
June 2019, the two companies entered into a licensing agreement to develop and commercialize Anwita's innovative IL-21 fusion protein AWT008 in Greater China.
the grant involved up to $66.5 million, while Regency Bio will subscribe for a $10 million stake in Anwita.
AWT008, Anwita's proprietary IL-21 fusion protein, has been shown in animal models with extended half-life and improved in vivo anti-tumor activity, and is designed to be developed as a single drug or in combination with other therapeutic drugs due to its mechanism of action.
IL-21 as an active cytokine that stimulates the activation of congenital and adaptive immune cells, such as NK cells and cytotoxic T cells.
.